drugset / Trial / NCT06905587
Methylphenidate in Pediatric Brain Tumor Survivors With Cancer-related Fatigue
Phase 3
Recruiting
50 enrolled
Odense University Hospital
Aalborg University Hospital · collabAarhus University Hospital Skejby · collabRigshospitalet, Denmark · collabUniversity of Southern Denmark · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
Cancer-related fatigue is a common and debilitating late effect in pediatric brain tumor survivors. Currently, evidence-based recommendations to ameliorate this condition are lacking. The researchers will investigate the ability of methylphenidate to improve fatigue and cognition in pediatric brain tumor survivors suffering from cancer-related fatigue. Methylphenidate is a drug (central nervous stimulant) most commonly used in the treatment of hyperkinetic disorders such as attention-deficit/hyperactivity disorder (ADHD). If methylphenidate shows an effect, the prospects are important for this patient group, since methylphenidate may then be included as part of the treatment of brain tumor-related fatigue.
Timeline
- Start
- 2025-09-02
- Primary completion
- 2029-12
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Methylphenidate | Small molecule | 10 mg | Oral |
| Subject | Methylphenidate | Small molecule | 15 mg | Oral |